Spyre Therapeutics
Update in progressSYRE (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on therapies for inflammatory bowel disease (IBD) and rheumatic diseases. It is developing SPY001, a humanized IgG1 antibody in Phase 2 that targets the α4β7 integrin for IBD; SPY002 and SPY072, anti-TL1A antibodies; SPY003, an IL-23–targeting program in Phase 2; and combinations SPY120 (anti-α4β7/TL1A), SPY130 (anti-α4β7/IL-23), and SPY230 (anti-TL1A/IL-23). Formerly Aeglea BioTherapeutics, it renamed Spyre in Nov 2023 and is based in Waltham, MA, founded 2013.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Cameron Turtle DPHIL, Ph.D.
- Founded2013
- Employees125
- Websitewww.spyre.com
Identifiers
- ISINUS00773J2024
- FIGIBBG0067L94B2
- CUSIP00773J202
- CIK0001636282